Literature DB >> 29073078

Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner.

Hee Jung Yang1, Jin Zhang2, Wensheng Yan1, Seong-Jun Cho3, Christopher Lucchesi1, Mingyi Chen4, Eric C Huang5, Ariane Scoumanne1, Weici Zhang6, Xinbin Chen2.   

Abstract

WT p53 is critical for tumor suppression, whereas mutant p53 promotes tumor progression. Nerve injury-induced protein 1 (Ninj1) is a target of p53 and forms a feedback loop with p53 by repressing p53 mRNA translation. Here, we show that loss of Ninj1 increased mutant p53 expression and, subsequently, enhanced cell growth and migration in cells carrying a mutant p53. In contrast, loss of Ninj1 inhibited cell growth and migration in cells carrying a WT p53. To explore the biological significance of Ninj1, we generated a cohort of Ninj1-deficient mice and found that Ninj1+/- mice were prone to systemic inflammation and insulitis, but not to spontaneous tumors. We also found that loss of Ninj1 altered the tumor susceptibility in both mutant p53 and p53-null background. Specifically, in a mutant p53(R270H) background, Ninj1 deficiency shortened the lifespan, altered the tumor spectrum, and increased tumor burden, likely via enhanced expression of mutant p53. In a p53-null background, Ninj1 deficiency significantly increased the incidence of T-lymphoblastic lymphoma. Taken together, our data suggest that depending on p53 genetic status, Ninj1 has two opposing functions in tumorigenesis and that the Ninj1-p53 loop may be targeted to manage inflammatory diseases and cancer. Published under the PNAS license.

Entities:  

Keywords:  Ninjurin 1; cell adhesion; inflammation; mutant p53; p53

Mesh:

Substances:

Year:  2017        PMID: 29073078      PMCID: PMC5664541          DOI: 10.1073/pnas.1711814114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions.

Authors:  Igal Ifergan; Hania Kebir; Simone Terouz; Jorge I Alvarez; Marc-André Lécuyer; Steve Gendron; Lyne Bourbonnière; Ildiko R Dunay; Alain Bouthillier; Robert Moumdjian; Adriano Fontana; Arsalan Haqqani; Armelle Klopstein; Marco Prinz; Rubèn López-Vales; Thomas Birchler; Alexandre Prat
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

Review 2.  IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.

Authors:  Markus F Neurath; Susetta Finotto
Journal:  Cytokine Growth Factor Rev       Date:  2011-03-05       Impact factor: 7.638

Review 3.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

4.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

5.  Contribution of Ninjurin1 to Toll-like receptor 4 signaling and systemic inflammation.

Authors:  Carla Jennewein; Ralf Sowa; Anne C Faber; Madlen Dildey; Andreas von Knethen; Patrick Meybohm; Bertram Scheller; Stefan Dröse; Kai Zacharowski
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

6.  Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.

Authors:  Wensheng Yan; Gang Liu; Ariane Scoumanne; Xinbin Chen
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

7.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

8.  Ninjurin1 suppresses metastatic property of lung cancer cells through inhibition of interleukin 6 signaling pathway.

Authors:  Yeong-Su Jang; Ju-Hee Kang; Jong Kyu Woo; Hwan Mook Kim; Jong-Ik Hwang; Sang-Jin Lee; Ho-Young Lee; Seung Hyun Oh
Journal:  Int J Cancer       Date:  2016-02-16       Impact factor: 7.396

9.  Ninjurin1 mediates macrophage-induced programmed cell death during early ocular development.

Authors:  H-J Lee; B J Ahn; M W Shin; J-W Jeong; J H Kim; K-W Kim
Journal:  Cell Death Differ       Date:  2009-06-26       Impact factor: 15.828

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  17 in total

1.  Measuring Translation Efficiency by RNA Immunoprecipitation of Translation Initiation Factors.

Authors:  Chris Lucchesi; Shakur Mohibi; Xinbin Chen
Journal:  Methods Mol Biol       Date:  2021

2.  FDXR regulates TP73 tumor suppressor via IRP2 to modulate aging and tumor suppression.

Authors:  Jin Zhang; Xiangmudong Kong; Yanhong Zhang; Wenqiang Sun; Jian Wang; Mingyi Chen; Xinbin Chen
Journal:  J Pathol       Date:  2020-05-18       Impact factor: 7.996

3.  NINJ1 mediates plasma membrane rupture during lytic cell death.

Authors:  Nobuhiko Kayagaki; Opher S Kornfeld; Bettina L Lee; Irma B Stowe; Karen O'Rourke; Qingling Li; Wendy Sandoval; Donghong Yan; Jing Kang; Min Xu; Juan Zhang; Wyne P Lee; Brent S McKenzie; Gözde Ulas; Jian Payandeh; Merone Roose-Girma; Zora Modrusan; Rohit Reja; Meredith Sagolla; Joshua D Webster; Vicky Cho; T Daniel Andrews; Lucy X Morris; Lisa A Miosge; Christopher C Goodnow; Edward M Bertram; Vishva M Dixit
Journal:  Nature       Date:  2021-01-20       Impact factor: 49.962

Review 4.  Mechanisms and Consequences of Noncanonical Inflammasome-Mediated Pyroptosis.

Authors:  Skylar S Wright; Swathy O Vasudevan; Vijay A Rathinam
Journal:  J Mol Biol       Date:  2021-09-16       Impact factor: 5.469

5.  p73α1, a p73 C-terminal isoform, regulates tumor suppression and the inflammatory response via Notch1.

Authors:  Kyra Nicole Laubach; Wensheng Yan; Xiangmudong Kong; Wenqiang Sun; Mingyi Chen; Jin Zhang; Xinbin Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-26       Impact factor: 12.779

6.  Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents.

Authors:  Yumiko Kawata-Shimamura; Hidetaka Eguchi; Reika Kawabata-Iwakawa; Mitsuhiko Nakahira; Yasushi Okazaki; Tetsuya Yoda; Reidar Grénman; Masashi Sugasawa; Masahiko Nishiyama
Journal:  BMC Cancer       Date:  2022-07-16       Impact factor: 4.638

7.  Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN.

Authors:  Jin Zhang; Enshun Xu; Cong Ren; Hee Jung Yang; Yanhong Zhang; Wenqiang Sun; Xiangmudong Kong; Weici Zhang; Mingyi Chen; Eric Huang; Xinbin Chen
Journal:  Cancer Res       Date:  2018-01-12       Impact factor: 12.701

8.  Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1.

Authors:  Jin Zhang; Wenqiang Sun; Xiangmudong Kong; Yanhong Zhang; Hee Jung Yang; Cong Ren; Yuqian Jiang; Mingyi Chen; Xinbin Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-11       Impact factor: 11.205

9.  Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis.

Authors:  Yanhong Zhang; Xiuli Feng; Jin Zhang; Minyi Chen; Eric Huang; Xinbin Chen
Journal:  Oncogene       Date:  2019-07-22       Impact factor: 8.756

10.  Mice Deficient in the RNA-Binding Protein Zfp871 Are Prone to Early Death and Steatohepatitis in Part through the p53-Mdm2 Axis.

Authors:  Shakur Mohibi; Jin Zhang; Mingyi Chen; Xinbin Chen
Journal:  Mol Cancer Res       Date:  2021-07-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.